

**Arnaud Bonnet,^a William Jones^a
 and W. D. Samuel Motherwell^{b*}**

^aThe Pfizer Institute for Pharmaceutical Materials Science, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, England, and ^bThe Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, England

Correspondence e-mail:
 motherwell@ccdc.cam.ac.uk

Key indicators

Single-crystal X-ray study
 T = 180 K
 Mean $\sigma(\text{C}-\text{C}) = 0.002 \text{ \AA}$
 R factor = 0.032
 wR factor = 0.101
 Data-to-parameter ratio = 13.1

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


***myo*-Inositol dihydrate: a redetermination**

The crystal structure of *myo*-inositol dihydrate, $\text{C}_6\text{H}_{12}\text{O}_6 \cdot 2\text{H}_2\text{O}$, previously reported by Lomer, Miller & Beevers [*Acta Cryst.* (1963), **16**, 264–268], has been redetermined, and the positions of the H atoms of the hydroxyl groups were located, showing an ordered hydrogen-bonding scheme.

Received 22 May 2006
 Accepted 9 June 2006

Comment

myo-Inositol (Fig. 1) is a biological molecule of nutritional and medical importance, which has been extracted from both plant and animal sources (Posternak, 1965). The crystal structure of the anhydrous form has previously been determined (Rabinovich & Kraut, 1964) and that of the dihydrate by Lomer *et al.* (1963).



In a series of experiments aimed at inhibiting the crystallization of *myo*-inositol from solution, we evaporated aqueous solutions of varying concentrations of *myo*-inositol and polyvinylpyrrolidone. Needle-shaped crystals formed as the solutions became more concentrated at room temperature. We




Figure 1
 The asymmetric unit of *myo*-inositol. Displacement ellipsoids are drawn at the 50% probability level.




Figure 2
myo-Inositol dihydrate, showing hydrogen-bonds (dashed lines) to the neighbouring molecules.




Figure 3
Packing diagram viewed in *a* axis projection, with *b* horizontal and *c* vertical. H atoms have been omitted for clarity. Hydrogen bonds are shown as dashed lines.

obtained the structure by single-crystal X-ray diffraction analysis at 180 K, confirming the dihydrate structure, with well located H atoms and a rational hydrogen-bonding scheme.

Each *myo*-inositol molecule forms a total of 13 intermolecular hydrogen bonds, defined as having O...O less than 3.04 Å. All 13 hydrogen bonds have normal bond lengths and geometry. The immediate hydrogen-bonded neighbours are six water molecules and four *myo*-inositol molecules (Fig. 2). Both water molecules show an optimal hydrogen-bond environment of two donor and two acceptor bonds. Each hydroxyl group on the inositol has a donor and acceptor hydrogen bond, with one (O3) forming (as an acceptor) a third hydrogen bond. The packing diagram (Fig. 3) shows an interesting feature where the water molecules link the inositol molecules in the *b*-axis direction, forming four-membered ring motifs H₂O...OH...H₂O...OH.

Experimental

An aqueous solution (10 ml) of *myo*-inositol (0.426 g) and polyvinylpyrrolidone (0.631 g) was prepared. The colourless solution was

allowed to evaporate at room temperature. When the solution had reduced to about half its initial volume, white needle-shaped crystals were observed and analysed by single-crystal X-ray diffraction. The crystals dehydrate prior to melting at 469 K.

Crystal data

C₆H₁₂O₆·2H₂O
M_r = 216.19
Monoclinic, *P*2₁/*n*
a = 6.6099 (2) Å
b = 16.6009 (4) Å
c = 9.0264 (2) Å
β = 110.751 (1)°
V = 926.22 (4) Å³

Z = 4
D_x = 1.550 Mg m⁻³
Mo *K*α radiation
μ = 0.15 mm⁻¹
T = 180 (2) K
Block cut from needle, white
0.46 × 0.35 × 0.23 mm

Data collection

Nonius KappaCCD diffractometer
Thin-slice ω and φ scans
Absorption correction: multi-scan
(*SORTAV*; Blessing, 1995)
*T*_{min} = 0.905, *T*_{max} = 0.968

7754 measured reflections
2104 independent reflections
1907 reflections with *I* > 2σ(*I*)
*R*_{int} = 0.019
θ_{max} = 27.5°

Refinement

Refinement on *F*²
R [*F*² > 2σ(*F*²)] = 0.032
wR (*F*²) = 0.101
S = 1.14
2104 reflections
161 parameters
H atoms treated by a mixture of independent and constrained refinement

$w = 1/[\sigma^2(F_o^2) + (0.0488P)^2 + 0.2568P]$
where $P = (F_o^2 + 2F_c^2)/3$
(Δ/σ)_{max} = 0.001
Δρ_{max} = 0.27 e Å⁻³
Δρ_{min} = -0.30 e Å⁻³

Table 1

Hydrogen-bond geometry (Å, °).

<i>D</i> —H... <i>A</i>	<i>D</i> —H	H... <i>A</i>	<i>D</i> ... <i>A</i>	<i>D</i> —H... <i>A</i>
O1—H1A...O7	0.82 (2)	2.02 (2)	2.8259 (13)	168 (2)
O2—H2A...O6 ⁱ	0.81 (2)	1.92 (2)	2.7275 (12)	175 (2)
O3—H3A...O5 ⁱⁱ	0.82 (2)	1.83 (2)	2.6454 (12)	173 (2)
O4—H4A...O7 ⁱⁱⁱ	0.81 (2)	2.02 (2)	2.8207 (12)	170 (2)
O5—H5A...O3 ^{iv}	0.84 (2)	1.80 (2)	2.6359 (12)	172 (2)
O6—H6A...O8	0.81 (2)	1.93 (2)	2.7365 (13)	176 (2)
O7—H7A...O8 ^v	0.82 (2)	2.18 (2)	2.9903 (14)	169 (2)
O7—H7B...O2 ^{vi}	0.84 (2)	2.01 (2)	2.8442 (13)	179 (2)
O8—H8A...O4 ^{vii}	0.82 (2)	2.23 (2)	3.0141 (13)	160 (2)
O8—H8A...O3 ^{viii}	0.82 (2)	2.45 (2)	3.0272 (13)	128 (2)
O8—H8B...O1 ^{viii}	0.83 (2)	2.03 (2)	2.8525 (13)	172 (2)

Symmetry codes: (i) $x + 1, y, z$; (ii) $x + \frac{1}{2}, -y + \frac{1}{2}, z - \frac{1}{2}$; (iii) $-x + \frac{1}{2}, y - \frac{1}{2}, -z + \frac{1}{2}$; (iv) $x - 1, y, z$; (v) $-x + 1, -y + 1, -z + 1$; (vi) $-x + 1, -y + 1, -z$; (vii) $x - \frac{1}{2}, -y + \frac{1}{2}, z + \frac{1}{2}$; (viii) $-x, -y + 1, -z + 1$.

All OH H atoms were located in the final difference map without any difficulty. The positions of the H atoms were refined independently and successfully, with a single O—H bond-length restraint [O—H = 0.807 (16)–0.844 (17) Å] and common *U*_{iso}(H) values for similar atoms [*U*_{iso}(H) = 0.44 (2) Å² for OH and *U*_{iso}(H) = 0.52 (3) Å² for H₂O]. The remaining H atoms were positioned geometrically, with C—H = 1.00 Å, and refined as riding with a common displacement parameter [*U*_{iso}(H) = 0.206 (14) Å²].

Data collection: *COLLECT* (Nonius, 1998); cell refinement: *SCALEPACK* (Otwinowski & Minor, 1997); data reduction: *SCALEPACK* and *DENZO* (Otwinowski & Minor, 1997); program(s) used to solve structure: *SIR92* (Altomare *et al.*, 1994); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *MERCURY* (Macrae *et al.*, 2006); software used to prepare material for publication: *SHELXL97*.

The authors are grateful to Dr John Davies (Department of Chemistry, University of Cambridge) for determining the crystal structure, and Drs A. Trask and L. Fabian for help with CIF preparation. The Pfizer Institute for Pharmaceutical Materials Science is acknowledged for funding the work.

References

- Altomare, A., Burla, M. C., Camalli, G., Cascarano, G., Giacovazzo, C., Guagliardi, A. & Polidori, G. (1994). *J. Appl. Cryst.* **27**, 435.
- Blessing, R. H. (1995). *Acta Cryst.* **A51**, 33–38.
- Lomer, T. R., Miller, A. & Beevers, C. A. (1963). *Acta Cryst.* **16**, 264–268.
- Macrae, C. F., Edgington, P. R., McCabe, P., Pidcock, E., Shields, G. P., Taylor, R., Towler, M. & van de Streek, J. (2006). *J. Appl. Cryst.* **39**, 453–457.
- Nonius, B. V. (1998). *COLLECT*. Nonius BV, Delft, The Netherlands.
- Otwinowski, Z. & Minor, W. (1997). *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A, edited by C. W. Carter Jr & R. M. Sweet, pp. 307–326. New York: Academic Press.
- Posternak, T. (1965). *The Cyclitols, Chemistry, Biochemistry, Biology*, edited by E. Lederer, pp. 284–286. Paris: Hermann.
- Rabinovich, H. N. & Kraut, J. (1964). *Acta Cryst.* **17**, 159–168.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.